Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Abstract 4013: Combination of BTK inhibitor orelabrutinib, anti-CD19 antibody tafasitamab, and IMiD lenalidomide for the treatment of B cell malignancies

Hongjuan Zhang, Ruixia Liang, Haipeng Xu, Xiaorong Li, Renbin Zhao, Jason Bin Zhang, Davy Xuesong Ouyang

Cancer Res (2023) 83 (7_Supplement): 4013.

https://doi.org/10.1158/1538-7445.AM2023-4013

Published: 04 April 2023

View articletitled, Abstract 4013: Combination of BTK inhibitor orelabrutinib, anti-CD19 antibody tafasitamab, and IMiD lenalidomide for the treatment of B cell malignancies

Journal Articles

Abstract 4012: Preclinical development of SHP2 allosteric inhibitor ICP-189

Ruixia Liang, Yingxiang Gao, Fangfang Yang, Yingrui Han, Zuopeng Wang, Richard Liu, Charles Ying Wang, Jason Bin Zhang, Xiangyang Chen, Davy Xuesong Ouyang

Cancer Res (2023) 83 (7_Supplement): 4012.

https://doi.org/10.1158/1538-7445.AM2023-4012

Published: 04 April 2023

View articletitled, Abstract 4012: Preclinical development of SHP2 allosteric inhibitor ICP-189

Journal Articles

Editor's Note: Activator Protein-1 Transcription Factors Are Associated with Progression and Recurrence of Prostate Cancer

Xuesong Ouyang, Walter J. Jessen, Hikmat Al-Ahmadie, Angel M. Serio, Yong Lin, Weichung-Joseph Shih, Victor E. Reuter, Peter T. Scardino, Michael M. Shen, Bruce J. Aronow, Andrew J. Vickers, William L. Gerald, Cory Abate-Shen

Cancer Res (2023) 83 (7): 1161.

https://doi.org/10.1158/0008-5472.CAN-23-0515

Published: 04 April 2023

View articletitled, Editor's Note: Activator Protein-1 Transcription Factors Are Associated with Progression and Recurrence of Prostate Cancer

Journal Articles

Abstract 3427: ICP-490 is a highly potent and selective IKZF1/3 degrader with robust anti-tumor activities against multiple myeloma and non-Hodgkin’s lymphoma

Ruixia Liang, Yucheng Pang, Yingrui Han, Haipeng Xu, Zuopeng Wang, Richard Liu, Charles Ying Wang, Jason Bin Zhang, Xiangyang Chen, Davy Xuesong Ouyang

Cancer Res (2023) 83 (7_Supplement): 3427.

https://doi.org/10.1158/1538-7445.AM2023-3427

Published: 04 April 2023

View articletitled, Abstract 3427: ICP-490 is a highly potent and selective IKZF1/3 degrader with robust anti-tumor activities against multiple myeloma and non-Hodgkin’s lymphoma

Journal Articles

Abstract 6187: ICP-723 is a potent pan-TRK Inhibitor with robust anti-tumor activities against wild-type and acquired drug-resistant mutations of NTRK fusions

Ruixia Liang, Chao Zhou, Yingrui Han, Prince Lu, Charles Ying Wang, Zuopeng Wang, Richard Liu, Norman Kong, Jason Bing Zhang, Jasmine Jisong Cui, Davy Xuesong Ouyang

Cancer Res (2022) 82 (12_Supplement): 6187.

https://doi.org/10.1158/1538-7445.AM2022-6187

Published: 15 June 2022

View articletitled, Abstract 6187: ICP-723 is a potent pan-TRK Inhibitor with robust anti-tumor activities against wild-type and acquired drug-resistant mutations of NTRK fusions

Journal Articles

Abstract 1808: Tracing T cell activation cytokines in reporter models by bioluminescent imaging

Ying Jin, Kaixia Lian, Fengge Li, Ruilin Sun, Annie X. An, Henry Q.x. Li, Davy Xuesong Ouyang

Cancer Res (2021) 81 (13_Supplement): 1808.

https://doi.org/10.1158/1538-7445.AM2021-1808

Published: 01 July 2021

View articletitled, Abstract 1808: Tracing T cell activation cytokines in reporter models by bioluminescent imaging

Journal Articles

Abstract 1814: Generation and validation of a novel humanized TNFR2 mouse model for the evaluation of therapeutic TNFR2 antibody

Xiaofeng Zhao, Ran Pang, Xiaoqing Liu, Wenjing Li, Xianfei He, Xuesong Ouyang, Zhuoxiao Cao, Renhong Tang, Wenqing Yang

Cancer Res (2021) 81 (13_Supplement): 1814.

https://doi.org/10.1158/1538-7445.AM2021-1814

Published: 01 July 2021

View articletitled, Abstract 1814: Generation and validation of a novel humanized TNFR2 mouse model for the evaluation of therapeutic TNFR2 antibody

Journal Articles

Abstract 1809: In vitro and in vivo characterization of human CD3EDG triple knock-in mice (CD3EDG HuGEMM™) for CD3 bispecific antibody evaluation

Daniel X. He, Lei Zheng, Tianyi Qian, Annie X. An, Henry Q.x. Li, Davy Xuesong Ouyang

Cancer Res (2021) 81 (13_Supplement): 1809.

https://doi.org/10.1158/1538-7445.AM2021-1809

Published: 01 July 2021

View articletitled, Abstract 1809: In vitro and in vivo characterization of human CD3EDG triple knock-in mice (CD3EDG HuGEMM™) for CD3 bispecific antibody evaluation

Journal Articles

Abstract 529: Characterization of a humanized TLR8 mouse model and its application in immuno-oncology drug development

Hongjuan Zhang, Ruilin Sun, Annie X. An, Henry Q.x Li, Davy Xuesong Ouyang

Cancer Res (2021) 81 (13_Supplement): 529.

https://doi.org/10.1158/1538-7445.AM2021-529

Published: 01 July 2021

View articletitled, Abstract 529: Characterization of a humanized TLR8 mouse model and its application in immuno-oncology drug development

Journal Articles

Abstract 2948: The impact of drinking water pH on anti-PD-1 efficacy in syngeneic mouse models

Ying Jin, Guangmao Mu, Fengge Li, Huajun Zhou, Annie X. An, Bonnie X. Chen, Henry Q.x Li, Davy Xuesong Ouyang

Cancer Res (2021) 81 (13_Supplement): 2948.

https://doi.org/10.1158/1538-7445.AM2021-2948

Published: 01 July 2021

View articletitled, Abstract 2948: The impact of drinking water pH on anti-PD-1 efficacy in syngeneic mouse models

Journal Articles

Abstract 3008: Characterization of a panel of orthotopic bioluminescent patient-derived models for drug discovery

Jessie Jingjing Wang, Jun Zhou, Ling Chen, Rongyun Zhou, Xiaoxi Xu, Henry Q. X. Li, Davy Xuesong Ouyang

Cancer Res (2021) 81 (13_Supplement): 3008.

https://doi.org/10.1158/1538-7445.AM2021-3008

Published: 01 July 2021

View articletitled, Abstract 3008: Characterization of a panel of orthotopic bioluminescent patient-derived models for drug discovery

Journal Articles

Abstract 1810: Anti-human TNFR2 antagonist induces T cell proliferation and restores T cell balance to promote tumor killing in TNFR2 HuGEMM™ engrafted with MC38/OVA tumor cells

Daniel X. He, Lei Zheng, Ruilin Sun, Annie X. An, Henry Q.x. Li, Davy Xuesong Ouyang

Cancer Res (2021) 81 (13_Supplement): 1810.

https://doi.org/10.1158/1538-7445.AM2021-1810

Published: 01 July 2021

View articletitled, Abstract 1810: Anti-human TNFR2 antagonist induces T cell proliferation and restores T cell balance to promote tumor killing in TNFR2 HuGEMM™ engrafted with MC38/OVA tumor cells

Journal Articles

Abstract 2947: Establishment and characterization of a series of murine cancer homograft models derived from induced cancer stem cells (iCSCs)

Jessie J. Wang, Likun Zhang, Annie X. An, Henry Q.X. Li, Davy Xuesong Ouyang

Cancer Res (2021) 81 (13_Supplement): 2947.

https://doi.org/10.1158/1538-7445.AM2021-2947

Published: 01 July 2021

View articletitled, Abstract 2947: Establishment and characterization of a series of murine cancer homograft models derived from induced cancer stem cells (iCSCs)

Journal Articles

Abstract 3005: Establishment and characterization of a series of lymphoma PDX models representing varied clinical behaviors and treatment responses

Jessie J. Wang, Yanrui Song, Jitai Zheng, Guiqing Wu, Likun Zhang, Henry Q.X. Li, Davy Xuesong Ouyang

Cancer Res (2021) 81 (13_Supplement): 3005.

https://doi.org/10.1158/1538-7445.AM2021-3005

Published: 01 July 2021

View articletitled, Abstract 3005: Establishment and characterization of a series of lymphoma PDX models representing varied clinical behaviors and treatment responses

Journal Articles

Abstract 5614: Combination of anti-TIGIT and anti-PD-1 antibodies enhance antitumor response in a PD-1/TIGIT double HuGEMM™ model engrafted with mouse syngeneic tumors

Daniel Xianfei He, Chenpan Nie, Lei Zheng, Ruilin Sun, Mingkun Zhang, Annie Xiaoyu An, Cunxiang Ju, Henry Q. X. Li, Davy Xuesong Ouyang

Cancer Res (2020) 80 (16_Supplement): 5614.

https://doi.org/10.1158/1538-7445.AM2020-5614

Published: 15 August 2020

View articletitled, Abstract 5614: Combination of anti-TIGIT and anti-PD-1 antibodies enhance antitumor response in a PD-1/TIGIT double HuGEMM™ model engrafted with mouse syngeneic tumors

Journal Articles

Abstract 5616: Characterization of a spectrum of DTR models for conditional depletion of specific immune cell lineages

Ying Jin, Jiahua Zhou, Fengge Li, Ruilin Sun, Annie Xiaoyu An, Henry Q. X. Li, Davy Xuesong Ouyang

Cancer Res (2020) 80 (16_Supplement): 5616.

https://doi.org/10.1158/1538-7445.AM2020-5616

Published: 15 August 2020

View articletitled, Abstract 5616: Characterization of a spectrum of DTR models for conditional depletion of specific immune cell lineages

Journal Articles

Abstract 5615: Anti-human CD47 antibody Hu5F9 inhibits MC38 tumor growth in hCD47/hSIRPα double knock-in mice

Daniel Xianfei He, Chenpan Nie, Lei Zheng, Ruilin Sun, Annie Xiaoyu An, Henry Q. x. Li, Davy Xuesong Ouyang

Cancer Res (2020) 80 (16_Supplement): 5615.

https://doi.org/10.1158/1538-7445.AM2020-5615

Published: 15 August 2020

View articletitled, Abstract 5615: Anti-human CD47 antibody Hu5F9 inhibits MC38 tumor growth in hCD47/hSIRPα double knock-in mice

Journal Articles

Abstract 2768: Development of a bioluminescent pancreatic orthotopic KPC model for immuno-oncology drug discovery

Yanrui Song, Phillip Shuzong Wang, Yinfei Yin, Henry Q. X. Li, Davy Xuesong Ouyang

Cancer Res (2020) 80 (16_Supplement): 2768.

https://doi.org/10.1158/1538-7445.AM2020-2768

Published: 15 August 2020

View articletitled, Abstract 2768: Development of a bioluminescent pancreatic orthotopic KPC model for immuno-oncology drug discovery

Journal Articles

Abstract 2788: Characterization of a panel of orthotopic syngeneic models using bioluminescent imaging for the evaluation of immuno oncology therapeutics

Diandong Jiang, Bryan Miller, Yanrui Song, Rajendra Kumari, Annie An, Jie Cai, Davy Xuesong Ouyang, Henry Qixiang Li, Yinfei Yin

Cancer Res (2020) 80 (16_Supplement): 2788.

https://doi.org/10.1158/1538-7445.AM2020-2788

Published: 15 August 2020

View articletitled, Abstract 2788: Characterization of a panel of orthotopic syngeneic models using bioluminescent imaging for the evaluation of immuno oncology therapeutics

Journal Articles

Abstract 4575: Efficacy proof of concept studies with universal mRNA vaccines in various mouse tumor models

Chenyan Wu, Tina Tingting Zhang, Xuefei Yan, Ying Jin, Henry Q. X. Li, Davy Xuesong Ouyang

Cancer Res (2020) 80 (16_Supplement): 4575.

https://doi.org/10.1158/1538-7445.AM2020-4575

Published: 15 August 2020

View articletitled, Abstract 4575: Efficacy proof of concept studies with universal mRNA vaccines in various mouse tumor models

Update search

NARROW

Format

Journal

Article Type

Issue Section

Date

Availability

Abstract 4013: Combination of BTK inhibitor orelabrutinib, anti-CD19 antibody tafasitamab, and IMiD lenalidomide for the treatment of B cell malignancies

Abstract 4012: Preclinical development of SHP2 allosteric inhibitor ICP-189

Editor's Note: Activator Protein-1 Transcription Factors Are Associated with Progression and Recurrence of Prostate Cancer

Abstract 3427: ICP-490 is a highly potent and selective IKZF1/3 degrader with robust anti-tumor activities against multiple myeloma and non-Hodgkin’s lymphoma

Abstract 6187: ICP-723 is a potent pan-TRK Inhibitor with robust anti-tumor activities against wild-type and acquired drug-resistant mutations of NTRK fusions

Abstract 1808: Tracing T cell activation cytokines in reporter models by bioluminescent imaging

Abstract 1814: Generation and validation of a novel humanized TNFR2 mouse model for the evaluation of therapeutic TNFR2 antibody

Abstract 1809: In vitro and in vivo characterization of human CD3EDG triple knock-in mice (CD3EDG HuGEMM™) for CD3 bispecific antibody evaluation

Abstract 529: Characterization of a humanized TLR8 mouse model and its application in immuno-oncology drug development

Abstract 2948: The impact of drinking water pH on anti-PD-1 efficacy in syngeneic mouse models

Abstract 3008: Characterization of a panel of orthotopic bioluminescent patient-derived models for drug discovery

Abstract 1810: Anti-human TNFR2 antagonist induces T cell proliferation and restores T cell balance to promote tumor killing in TNFR2 HuGEMM™ engrafted with MC38/OVA tumor cells

Abstract 2947: Establishment and characterization of a series of murine cancer homograft models derived from induced cancer stem cells (iCSCs)

Abstract 3005: Establishment and characterization of a series of lymphoma PDX models representing varied clinical behaviors and treatment responses

Abstract 5614: Combination of anti-TIGIT and anti-PD-1 antibodies enhance antitumor response in a PD-1/TIGIT double HuGEMM™ model engrafted with mouse syngeneic tumors

Abstract 5616: Characterization of a spectrum of DTR models for conditional depletion of specific immune cell lineages

Abstract 5615: Anti-human CD47 antibody Hu5F9 inhibits MC38 tumor growth in hCD47/hSIRPα double knock-in mice

Abstract 2768: Development of a bioluminescent pancreatic orthotopic KPC model for immuno-oncology drug discovery

Abstract 2788: Characterization of a panel of orthotopic syngeneic models using bioluminescent imaging for the evaluation of immuno oncology therapeutics

Abstract 4575: Efficacy proof of concept studies with universal mRNA vaccines in various mouse tumor models

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only